If you are interested in participating in a clinical trial but just can not figure out how to navigate the government's clinical trial web page (www.clinicaltrials.gov) you could call 1-800-4-CANCER for assistance. This number will put you in touch with the National Cancer Institute's (NCI) Center for Cancer Research. The operators who answer the phone [...]
Based on six recent retrospective analyses comparing the gonadotropin-releasing hormone (GnRH) antagonist degarelix against the traditional luteinizing hormone-releasing hormone (LHRH) agonists (i.e. Zoladex, Lupron etc.) men with advanced prostate cancer experienced improved disease control, fewer instances of urinary infections, and a lower risk of cardiovascular events. The six analyses compared data from randomized trials that [...]
The number of cancer survivors is increasing, soon to be as many of 13 million of us in the world! Bones are often affected in cancer survivors, usually a result of bone metastases, or of anti-cancer therapies which can contribute to bone loss and fragility. Bone disease in cancer survivors can result both from the [...]
Becoming a full time 24/7 caregiver for someone with any chronic illness, including advanced prostate cancer is overwhelming. Most caregivers find that they stop their own personal activities, including those that give them personal pleasure. Caregiving means subverting personal needs in favor of the needs of the patient. This situation often leads to the [...]
We are in the fortunate position because the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) continues to evolve as new agents with the ability to extend survival gain FDA approval. The most recently FDA approved treatment, the alpha emitting radiopharmaceutical radium-223 (Xofigo) was approved for men with bone metastatic prostate cancer. Most other [...]